ABCD position statement on glitazones

Practical Diabetes International

Volumn 21, Issue 8, 2004, Pages 293-295

  Higgs, E R ^a   Krentz, A J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOTRANSFERASE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; DIABETIC OBESITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLUID RETENTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PUBLICATION; SCREENING; UNITED KINGDOM;

EID: 13244283025     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.694     Document Type: Article

References (10)

1. Bailey CJ, Day C, Krentz A. Nice timing for glitazones. Br J Diabetes Vasc Dis 2003; 3: 308-309.
2. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326: 4-5.
3. Lebovitz H, Dole JF, Patwardhan, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. JCEM 2001; 86: 280-288.
4. Aronoff SL, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycaemic control in the treatment of patients with type 2 diabetes: a 6-month randomised placebo-controlled study. Diabetes Care 2000; 23: 1605-1611.
5. Morjaria HK, Lawrence IG, Jarvis J, et al. Clinical effectiveness of pioglitazone in triple therapy in type 2 diabetes mellitus. Diabetic Med 2002; 19(Suppl 2): P42.
6. Kiayias JA, Vlachou ED, Theodosopoulou E, et al. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care 2002; 25: 1251-1252.
7. Levy D, James A, Liew L, et al. Prospective audit of triple therapy in poorly controlled Type 2 diabetes: enhanced response in South Asian people. Diabetic Med 2004; 21(Suppl 2): A49.
8. Nesto RW, Bell D, Borrow RO, et al. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-263.
9. Raskin P, Rendell M, Riddle MC, et al. A randomised trial of Rosiglitazone therapy in patents with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1212.
10. Promrat K , Lutchman G, Uwaifa GI, et al. A pilot study of pioglitazone treatment for non-alcoholic steato-hepatitis. Hepatology 2004; 39: 188-196.